Galapagos Reports Promising Phase III Data in Rheumatoid Arthritis
Clara Rodríguez Fernández on 12/09/2018
The inflammation market is huge, expected to reach over €100Bn by 2020. The world’s best-selling drug, Humira (adalimumab) is indicated against multiple inflammatory conditions, including rheumatoid arthritis. By targeting patients that do not respond to biological drugs like Humira, Galapagos could have a competitive advantage in this market. However, it will be facing competition from its previous partner AbbVie.
Before the partnership with Gilead, Galapagos was working with AbbVie in the development of filgotinib. However, the big pharma walked out of their agreement in 2015 and is now developing its own candidate drug for rheumatoid arthritis. AbbVie’s drug candidate, upadacitinib, which has a similar mechanism of action to filgotinib’s, also yielded in April.
Meet these Successful Biotechs at Biospain 2018!